

REMARKS

The September 16, 2004 Office Action rejected pending claims 1-12. For the reasons set forth in Applicants' Response filed on June 21, 2004, Applicants respectfully traverse the rejections of these claims.

However, the Office Action appears to admit that sequences 1-4 are enabled. In particular, the Office Action states that claims 1-12 are "enabled for a pharmaceutical composition using alpha-MSH ending in SEQ ID NO: 1, KPV" (September 16, 2004 Office Action, p. 2). Further, the Office Action appears to admit that Applicants have provided sufficient enabling disclosure for the use of SEQ. ID. NOS: 1-4 for the treatment of sinusitis. In particular, the September 16 Office Action states: "Applicant has only provided guidance for the use of SEQ ID NO:1-4 in the treatment of sinusitis" (September 16, 2004 Office Action, p. 2).

Notwithstanding Applicants' traversal, Applicants have amended claims 1-2 and therefore rendered the rejections moot.

CONCLUSION

In view of the foregoing claim amendments, which are made in light of comments appearing in the September 16, 2004 Office Action, it is submitted that the claims are in condition for allowance. Therefore, a Notice of Allowance is respectfully requested.

Dated: 12-16, 2004

Respectfully submitted,

Customer No. 34055
Perkins Coie LLP
Patent - LA
P.O. Box 1208
Seattle, WA 98111-1208
Phone: (310) 788-9900
Fax: (206) 332-7198

PERKINS COIE LLP

By: 

James J. Zhu
Reg. No. 52,396